AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03725878 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard tertiary interventions of birth defects
Description: Couples eligible for reproductive policy are entitled to routine health cares including general health cares (health education, medical history inquiry, physical examinations, consulting guidance and pregnancy outcome follow-up) and medical examinations (laboratory examinations, virus screenings and image examinations). But nutrients status are not included in these examinations, such as folate, vitamin B12, and macroelements, et al. Regular antenatal cares are required, such as deformity screening by ultrasound. Routine neonatal screenings are conducted to diagnose infant with birth defect timely.
Study NCT03725878 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Additional preconception health care
Description: Various studies have revealed that folate is essential in early embryo development, whereas folate level evaluation in periconception women is not included in routine health cares. Therefore, we evaluate subject's folate level by serum and red blood cell folate examination. By combination of folate supplement obtained by questionnaire,folate level evaluated by examinations and folate metabolism ability evaluated by genotyping key enzymes in folate metabolism, an individualized folic acid supplementary guide is given to subjects. Red blood cell folate concentration >400 ng/ml before pregnancy is recommended.
Study NCT03725878 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Additional health care procedures during and after pregnancy
Description: Fetus with birth defect will be referred to a tertiary hospital to receive genetic assessments and prenatal diagnosis to reduce unnecessary abortions. A 6-months follow up will be conducted to follow children's birth outcomes. It also helps clinical team to give early diagnosis and treatment for children with birth defect to reduce disability and improve life quality of defect children.
Study NCT03725878 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Additional health care procedures during and after pregnancy
Description: Fetus with birth defect will be referred to a tertiary hospital to receive genetic assessments and prenatal diagnosis to reduce unnecessary abortions. A 6-months follow up will be conducted to follow children's birth outcomes. It also helps clinical team to give early diagnosis and treatment for children with birth defect to reduce disability and improve life quality of defect children.
Study NCT03709654 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NB01
Description: 5-7 day pretreatment of gold standard benzoyl peroxide therapy to kill resident facial bacterial followed by 11 weeks of daily topical application of NB01
Study NCT03709654 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Control
Description: 5-7 day pretreatment of gold standard benzoyl peroxide therapy to kill resident facial bacterial followed by 11 weeks of daily topical application of vehicle control
Study NCT01166022 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Muscle strengthening program using hand weights and resistance bands in combination with a home based cycle ergometry. This home-based exercise program will be performed up to 5 times weekly. Each session will consist of up to 30 minutes of cycling and 30 minutes of strengthening.
Study NCT00766532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase Inhibitor
Description: Any aromatase inhibitor started as initial adjuvant therapy
Study NCT03672019 — intervention group
Intervention type: BEHAVIORAL
Intervention: FACT-Hep
Description: Patient Reported Outcomes (PRO) assessments at baseline and at three time points post-procedure: 4 weeks (+/- 1 weeks), 12 weeks (+/- 2 weeks), and 6 months (+/- 2 weeks).
Study NCT03241914 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Megestrol Acetate
Description: At a dosage of 160 mg/day
Study NCT03241914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Megestrol Acetate
Description: At a dosage of 160 mg/day
Study NCT03241914 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing Intrauterine System(LNG-IUS)
Description: levonorgestrel 52mg. It is a hormone-releasing T-shaped intrauterine system.
Study NCT03951623 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HMPL-523
Description: HMPL-523 will be oral administrated once daily for 8 weeks and 16 weeks open-label treatment.
Study NCT03951623 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HMPL-523
Description: HMPL-523 will be oral administrated once daily for 8 weeks and 16 weeks open-label treatment.
Study NCT03951623 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: HMPL-523 matching placebo will be oral administrated once daily for 8 weeks and 16 weeks open-label treatment.
Study NCT01836432 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRINOX
Description: FOLFIRINOX consisting of Oxaliplatin 85 mg/m\^2 IV over 2 hours; Irinotecan 180 mg/m\^2 IV over 90 minutes; Leucovorin 400 mg/m\^2 IV over 2 hours; Fluorouracil 2.4 g/m\^2 IV over 46 hours
Study NCT01836432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Description: FOLFIRINOX consisting of Oxaliplatin 85 mg/m\^2 IV over 2 hours; Irinotecan 180 mg/m\^2 IV over 90 minutes; Leucovorin 400 mg/m\^2 IV over 2 hours; Fluorouracil 2.4 g/m\^2 IV over 46 hours
Study NCT01836432 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Algenpantucel-L Immunotherapy
Description: Algenpantucel-L Immunotherapy (HAPa) consisting of 300 Million HAPa cells given by intradermal injection
Study NCT01836432 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU Chemoradiation
Description: 5-FU Chemoradiation consisting of 5-FU continuous IV infusion of 200-250 mg/m\^2/day given 5-7 days each week over 5.5 weeks concurrently with external beam radiation
Study NCT01836432 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 5-FU Chemoradiation
Description: 5-FU Chemoradiation consisting of 5-FU continuous IV infusion of 200-250 mg/m\^2/day given 5-7 days each week over 5.5 weeks concurrently with external beam radiation
Study NCT01599624 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Resilience Training System (SRTS)
Description: SRTS training provides both cognitive learning and training in a scientifically-designed stress resilience training approach designed to minimize the adverse effects of stress and also enhance its positive effects. In summary, the SRTS training comprises: (1) Cognitive rules and mental exercises based on expert knowledge and research; (2) Biofeedback stress control exercises based on proven HRV (Heart Rate Variability) algorithms developed by the Institute of HeartMath; and (3) E-Learning presentation of games and simulations to motivate younger trainees. The training is designed to familiarize participants with the iPad and the SRTS program. Participants will be told how to use the system and how often to use the system. SRTS program participants will each be assigned an iPad to take home with them and practice the techniques for a period of two months.
Study NCT01836432 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m\^2 given intravenously over 30 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest.
Study NCT01836432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m\^2 given intravenously over 30 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest.
Study NCT01836432 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine consisting of 825 mg/m\^2 PO BID M-F concurrently with external beam radiation
Study NCT01836432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine consisting of 825 mg/m\^2 PO BID M-F concurrently with external beam radiation
Study NCT01836432 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-Paclitaxel
Description: Nab-Paclitaxel 125 mg/m\^2 given intravenously over 30-40 minutes
Study NCT01836432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: Nab-Paclitaxel 125 mg/m\^2 given intravenously over 30-40 minutes
Study NCT01599624 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR)
Description: Progressive muscle relaxation is the systematic tensing and relaxing of 16 different muscle groups, starting with one's toes and ending with one's head (Jacobson, 1938; Conrad \& Roth, 2007). PMR users are instructed to inhale as they tense the muscles and exhale as they release the tension. Participants will participate in a two-hour PMR training. PMR participants will be given iPADs with a video recording that guides the user through working each muscle group while instructing them to focus on positive thoughts and feelings and breathing techniques. PMR program participants will each be assigned an iPad to take home with them and practice the techniques for a period of two months.
Study NCT01864603 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Universal ART in a streamlined care model
Description: immediate ART start for all HIV+ in community with streamlined care
Study NCT02287974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stem cell infusion
Description: Unique stem cell infusion of the randomized group
Study NCT02287974 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stem cell infusion
Description: Unique stem cell infusion of the randomized group
Study NCT00272909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: piclozotan low dose
Description: Continuous IV infusion over a period of up to 72 hours of piclozotan
Study NCT00272909 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Continuous IV infusion over a period of up to 72 hours of placebo.
Study NCT00272909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: piclozotan high dose
Description: Continuous IV infusion over a period of up to 72 hours of piclozotan
Study NCT02006342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Study NCT01864603 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Universal ART in a streamlined care model
Description: immediate ART start for all HIV+ in community with streamlined care
Study NCT01864603 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Annual Community Health Campaigns
Description: HIV and multi-disease testing for all community members
Study NCT01864603 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Targeted PrEP and Targeted testing interventions
Study NCT02006342 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regular Insulin
Study NCT02006342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regular Insulin
Study NCT02474212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Study NCT04217187 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation
Description: Upper extremity neuromuscular electrical stimulation
Study NCT04217187 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Electrical Stimulation
Description: Sensory only upper extremity electrical stimulation
Study NCT02855528 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tin Filter
Study NCT01489566 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tyroserleutide for injection ,chemotherapy(mitomycin, and Fluorouracil )
Description: mitomycin(10mg)+Fluorouracil(1.0g),through the chemoradiative pump,every cycle,5-30 minites; Tyroserleutide for injection(30mg) ,through the micro infusion pump,every cycle,3-5 days
Study NCT01489566 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: the placebo ,chemotherapy(mitomycin, and Fluorouracil )
Description: mitomycin(10mg)+Fluorouracil(1.0g),through the chemoradiative pump,every cycle,5-30 minites; the placebo(30mg) ,through the micro infusion pump,every cycle,3-5 days
Study NCT00893724 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Neutral pills with no medicinal effect
Description: Neutral pills with no medicinal effect
Study NCT00893724 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Inosine; Tocopherols, Tocotrienol, CoQ10 combination capsule; Niacinamide SR; Viatmin C; N-acetyl Cysteine; Complete Multivitamin with all minerals
Description: Inosine \[SR\] - 1\[500mg\] tablet bid Tocopherols \[200IU\], Tocotrienol \[10mg\], CoQ10 \[50mg\] - combination capsule bid Sustained Release Niacinamide - 1 \[750mg\] tablet bid Vitamin C - 1 \[1000mg\] sustained release tablet bid N-acetyl Cysteine - 1 \[600mg\] sustained release tablet qd Complete Multivitamin with all minerals - 1 tablet (sustained release) bid
Study NCT00893724 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inosine; Tocopherol, Tocotrienol, CoQ10 combination capsule; Niacinamide; Vitamin C; N-acetyl Cysteine; Complete Multivitamin with all minerals; Minocycline
Description: Inosine \[SR\] - 1 \[500mg\] tablet bid Tocopherol \[200IU\], Tocotrienol \[10mg\], CoQ10 \[50mg\] combination capsule bid Sustained Release Niacinamide 1 \[750mg\] tablet bid Vitamin C 1 \[1000mg\] sustained release tablet bid N-acetyl Cysteine 1 \[600mg\] sustained release tablet qd Complete Multivitamin with all minerals - 1 tablet (sustained release) bid Minocycline 1 \[50mg\] tablet qd
Study NCT02820311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-4208 175 mcg
Description: via nebulizer
Study NCT02820311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-4208 700 mcg
Description: via nebulizer
Study NCT02820311 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for TD-4208
Description: via nebulizer
Study NCT01864603 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Baseline community-based HIV and multi-disease testing
Description: HIV and multi-disease testing for all community members at baseline only
Study NCT02820311 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin 400 mg
Description: oral
Study NCT00334022 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: enfuvirtide
Description: 1ml BID
Study NCT00334022 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: enfuvirtide
Description: 1ml BID
Study NCT01577186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Description: Participants will receive paliperidone ER tablet in flexible dose range of 3 to 12 milligram per day (mg/day) orally once daily up to Week 12 as per Investigator's discretion.
Study NCT03287219 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylene Blue MMX 25 mg modified release tablets
Description: Methylene Blue MMX 25 mg modified release tablets administered with a full dose regimen of a 4-L PEG-based bowel cleansing preparation.
Study NCT02441296 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Formula with lactose
Study NCT02441296 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Formula with maltodextrins
Study NCT01090661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mipomersen sodium
Description: 200 mg of mipomersen intravenous (IV) (single dose)
Study NCT01090661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mipomersen sodium
Description: 200 mg of mipomersen subcutaneous (SC) (single dose)
Study NCT01090661 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxacin hydrochloride (Avelox®)
Description: 400 mg of moxifloxacin intravenous (IV) single dose
Study NCT01090661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo intravenous (IV) single dose
Study NCT01090661 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo intravenous (IV) single dose
Study NCT01090661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo subcutaneous (SC) single dose
Study NCT01090661 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo subcutaneous (SC) single dose
Study NCT01090661 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo subcutaneous (SC) single dose
Study NCT02446899 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anifrolumab
Description: Intravenous infusion (IV)
Study NCT02446899 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion (IV)
Study NCT04663659 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT02165267 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC01
Description: Administered IV in 100 mL of normal saline (Sodium Chloride for Injection 0.9%, USP) or administered SC by needle and syringe injection.
Study NCT02738983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib (trade name: Tarceva®) or Icotinib (trade name: Conmana®)
Description: Erlotinib (trade name: Tarceva®) (150mg oral daily) or Icotinib (trade name: Conmana®) (125mg oral three times a day).
Study NCT02738983 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Concurrent radiotherapy total dose 60-66 Gy in 2 Gy fractions. One fraction per day, and 5 fractions per week.
Study NCT01118351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: Given orally
Study NCT01118351 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies
Study NCT01118351 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TdT-mediated dUTP nick end labeling assay
Description: Correlative studies
Study NCT01118351 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: light microscopy
Description: Correlative studies
Study NCT01118351 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02413112 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Whole-body resistance training in the University gym that is supervised by researchers.~Training once per week, Training twice per week, Training thrice per week.
Study NCT02165267 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: SC placebo for VRC01
Description: Sterile, buffered aqueous solution of 25 mM Sodium Citrate, 50 mM Sodium Chloride, 150 mM L-Arginine Hydrochloride, 10% Dextran 40, and 0.005% Polysorbate 80 at pH 5.8 administered SC by needle and syringe injection
Study NCT02165267 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: IV placebo for VRC01
Description: Sodium Chloride for Injection 0.9%, USP administered IV in 100 mL of normal saline (Sodium Chloride for Injection 0.9%, USP)
Study NCT01757353 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BASICS motivational interview
Study NCT00746980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: efalizumab
Description: 1 mg/kg subcutaneously once weekly for 48 weeks, following an initial conditioning dose of 0.7 mg/kg at week 0.
Study NCT03569709 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise
Description: Progressive sub-threshold aerobic exercise
Study NCT03569709 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Rest
Description: No structured exercise.
Study NCT01757353 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BASICS plus normative enhancement motivational interview
Study NCT01757353 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-directed: Information only
Study NCT03569709 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Stretching
Description: Gentle progressive upper and lower extremity stretching program
Study NCT02731209 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: urinary catheter
Study NCT03587454 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Teleglaucoma
Description: Subjects are evaluated through a teleglaucoma protocol then by physical presence in a glaucoma clinic
Study NCT01437852 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: StrataGraft Skin Tissue
Study NCT03114514 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP
Description: PRP will be injected subcutaneously around the eyes at three different time points with one-month interval
Study NCT03500900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 mg
Description: Acute administration of Vildagliptin, 50 mg.
Study NCT00436345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: analgesia in medical and post-surgical Intensive Care Unit subjects requiring mechanical ventilation
Study NCT03500900 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Acute administration of placebo tablet
Study NCT01934556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab 0.3 mg intravitreal injection
Study NCT01934556 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Guided Laser Photocoagulation